<

Glumetza(r) Market Potential 15 (CHART) 0.4M

NasdaqGS: SNTS July 9, 2013

Exhibit 99.1

Q2 2013 Financial Results

Bausch + Lomb Update

Changing the management of hemostasis in surgery ...

LOGO

several near term value drivers 19 event expected timing ...

Thank You! Intellipharmaceutics | Investor Presentation ...

Slide 6

2013 FDA and EMA Approval Report - ppt download

4 Agenda Creating the global leader in Rare Diseases ...

Exhibit 99.1

Back to School with PDUFA

GRAPHIC

GRAPHIC

Glumetza(r) Market Potential 15 (CHART) 0.4M

When the FDA Plays God, Investors Make a Killing ...

Exhibit99.2

2013 FDA and EMA Approval Report - ppt download

Agile Therapeutics (AGRX) Investor Presentation ...

LOGO

7 Yuvvexy TM TX - 004HR | Vulvar and Vaginal Atrophy (VVA ...

4 q13 presentation final

Monthly Magazine - Pharma Uptoday Volume 9, Issue Dec 2014

GRAPHIC

FDA Grants Spectrum Pharmaceuticals Accelerated Approval ...

Best Idea For 2014: Sanofi Rights Post-FDA Approval ...

Cancer on Pinterest

AEterna Zentaris Inc. (USA) (AEZS) Announces NDA Filing ...

MannKind: Do Insider Sales Transactions Indicate This Is A ...

20 lipocine is a compelling value proposition stock ...

Annual Results 2014

VEN 307: Commercial Overview

EAGLE PHARMACEUTICALS, INC. - FORM 8-K - EX-99.1 - May 8, 2014

GRAPHIC

Bausch + Lomb Update

H.C. Wainwright Reiterates Buy On Aeterna Zentaris ...

MannKind: Do Insider Sales Transactions Indicate This Is A ...

shearlings got plowed: On Same Day As Merck's Tender Offer ...

Newly Approved Vimizim Ready To Enter Market Immediately ...

Bausch + Lomb Update

Abuse-Deterrent Opioids Prevent Users From Intensifying High